Recently,
the first monoclonal antibody drug Daratumumab by the US Food and Drug
Administration (FDA) approved for the treatment of multiple myeloma
(MM). For at least three kinds of therapy by the patients, the drug is an excellent treatment option.
FDA said the two open studies have demonstrated the safety and effectiveness of the drug. One
study included 106 patients with MM and give daratumumab treatment, the
results are 29% of the patients had a complete tumor burden or partial
reduction, and lasted an average of 4.7 months. And
another study, 42 MM patients received the drug treatment, the results
of 36% of the patients had a complete tumor burden or partially reduced.
The researchers said that to ease daratumumab produced is "unprecedented".
Professor Peter Voorhees said the study 106 patients received daratumumab monotherapy, and 29% of patients had a remission. What is more, 95% of all patients on protease inhibitor and lenalidomide therapy has become resistant. In addition, its ease lasting effect. More importantly, none of the patients in the study because of side effects associated daratumumab stop treatment.
FDA
said the drug's side effects include infusion reactions, fatigue,
nausea, back pain, fever and cough, and may cause lymphopenia,
neutropenia, leukopenia, anemia and thrombocytopenia. This medicine should not be used during pregnancy Women, pregnancy or
the wishes of the patient must stop taking this medicine for effective
contraception after three months.
In addition, daratumumab may affect some blood bank tests (eg, antibody screening, etc.).
Daratumumab is the first anti-human CD38 monoclonal antibody, induces cell death through multiple mechanisms. The drug is given priority review by the FDA's accelerated approval. FDA granted the drug for the treatment of multiple myeloma orphan drug status.
2015年11月18日星期三
PDX may be used as an ideal model for advanced pancreatic cancer
Pancreatic
ductal adenocarcinoma is a very high mortality rate of malignant
cancer, a disease that has the ability to aggressive and fast-moving, so
the pancreatic ductal adenocarcinoma is still a very difficult to treat clinical disease. If
you can on the incidence and mechanisms of invasion and metastasis of
pancreatic ductal adenocarcinoma have a more in-depth understanding, it
will greatly promote the development of drugs and treatments, but there
is still a lack of late-stage cancer to represent an ideal model of
disease. In addition, PDX animal models before clinical trials for cancer among
patients with carcinoma in situ molecular similarity how are still
unknown.
To find potential metastatic pancreatic cancer progression driving molecule, scientists from the United States and Spain, in situ tumors from an autopsy project, metastatic tumor and normal samples (peripheral blood) were full-exon, and they also constructed corresponding PDX model, also we were sequenced, and compared with the patient's tumor.
After the sequence data from three patients were analyzed, the researchers found that the presence of 160 single nucleotide mutation in each tumor sample average, the majority of mutations are present in each patient's tumor and metastases in situ, more It is important that most of these mutations are retained in the PDX model.
Based on in-situ tumors and metastases mutation rate, the researchers propose possible cloning evolution model that exists in the function mutations affect some important oncogenes, such as KRAS, TP53, and SMAD4, these oncogenes are tumorigenesis and metastasis plays an important role.
To find potential metastatic pancreatic cancer progression driving molecule, scientists from the United States and Spain, in situ tumors from an autopsy project, metastatic tumor and normal samples (peripheral blood) were full-exon, and they also constructed corresponding PDX model, also we were sequenced, and compared with the patient's tumor.
After the sequence data from three patients were analyzed, the researchers found that the presence of 160 single nucleotide mutation in each tumor sample average, the majority of mutations are present in each patient's tumor and metastases in situ, more It is important that most of these mutations are retained in the PDX model.
Based on in-situ tumors and metastases mutation rate, the researchers propose possible cloning evolution model that exists in the function mutations affect some important oncogenes, such as KRAS, TP53, and SMAD4, these oncogenes are tumorigenesis and metastasis plays an important role.
A healthy diet may reduce a woman's risk of ovarian cancer
The level of medical health disparities eighth annual meeting of the
American race science and Minority Cancer American Association for
Cancer Research (AACR) organized a study data showed that a healthy diet
can reduce the risk of ovarian cancer in African-American women.
Bo (Bonnie) Qin, PhD, said "For ovarian cancer, there is no reliable screening program, most in the diagnosis of ovarian cancer is already advanced stage, so identifying factors that can prevent vital life, including dietary intervention . "
In the United States, ovarian cancer is the fifth cause of cancer death in women causes. African-American women to lower rates of the disease diagnosis, but the mortality rate is higher. Qin of 415 women with ovarian cancer and 629 control patients conducted a study to explore the improved diet can reduce the risk of ovarian cancer, African American women.
Ovarian cancer patients completed one year of diagnosis of ovarian precancerous questionnaires on diet in the control group completed the same questionnaire. We evaluated three diet types: HEI-2005 based on the federal Dietary Guidelines for Americans; HEI-2010 reflects the most recent dietary guidelines, and stressed eating quality; AHEI-2010 based on different nutritional guidance, healthy eating pyramid.
Qin said that "adherence to AHEI-2010 best female group diagnostics compliance than the worst risk of ovarian cancer by 34% smaller."
Postmenopausal women, HEI-2010 score in the highest quartile small 43%, AHEI-2010 scored the highest quartile diagnosis of ovarian cancer than the lowest 51 percent less likely to the least likely of the diagnosis of ovarian cancer than.
Qin said the "HEI-2010 dietary intake of vegetables, green vegetables, beans, seafood and vegetable protein intake of fewer calories meaningless solid fat, alcohol, added sugar; AHEI-2010 dietary intake just more vegetables and fewer sugary drinks and fruit juices; these are beneficial to the people. "
There are many diets common element, AHEI-2010 concrete proposals more protein and fat sources include nuts, legumes, ω- 3 fatty acids EPA and DHA. Use energy density method HEI-2010, according to a person's recommended daily nutritional diet optimal intake.
Qin said the "Future studies also need to determine the impact of different aspects of a healthy diet on the risk of ovarian cancer, as well as specific nutritional impact of the disease.""As a high-quality diet is beneficial for many chronic diseases, but also a safe choice for better health."
Qin said the main limitation of the study is that the study patients were asked to recall the year before diagnosis diet research that led to the presence of recall bias and inaccurate reporting.
Bo (Bonnie) Qin, PhD, said "For ovarian cancer, there is no reliable screening program, most in the diagnosis of ovarian cancer is already advanced stage, so identifying factors that can prevent vital life, including dietary intervention . "
In the United States, ovarian cancer is the fifth cause of cancer death in women causes. African-American women to lower rates of the disease diagnosis, but the mortality rate is higher. Qin of 415 women with ovarian cancer and 629 control patients conducted a study to explore the improved diet can reduce the risk of ovarian cancer, African American women.
Ovarian cancer patients completed one year of diagnosis of ovarian precancerous questionnaires on diet in the control group completed the same questionnaire. We evaluated three diet types: HEI-2005 based on the federal Dietary Guidelines for Americans; HEI-2010 reflects the most recent dietary guidelines, and stressed eating quality; AHEI-2010 based on different nutritional guidance, healthy eating pyramid.
Qin said that "adherence to AHEI-2010 best female group diagnostics compliance than the worst risk of ovarian cancer by 34% smaller."
Postmenopausal women, HEI-2010 score in the highest quartile small 43%, AHEI-2010 scored the highest quartile diagnosis of ovarian cancer than the lowest 51 percent less likely to the least likely of the diagnosis of ovarian cancer than.
Qin said the "HEI-2010 dietary intake of vegetables, green vegetables, beans, seafood and vegetable protein intake of fewer calories meaningless solid fat, alcohol, added sugar; AHEI-2010 dietary intake just more vegetables and fewer sugary drinks and fruit juices; these are beneficial to the people. "
There are many diets common element, AHEI-2010 concrete proposals more protein and fat sources include nuts, legumes, ω- 3 fatty acids EPA and DHA. Use energy density method HEI-2010, according to a person's recommended daily nutritional diet optimal intake.
Qin said the "Future studies also need to determine the impact of different aspects of a healthy diet on the risk of ovarian cancer, as well as specific nutritional impact of the disease.""As a high-quality diet is beneficial for many chronic diseases, but also a safe choice for better health."
Qin said the main limitation of the study is that the study patients were asked to recall the year before diagnosis diet research that led to the presence of recall bias and inaccurate reporting.
Doctors need to request the use of antibiotics in patients with caution
Antibiotics to treat bacterial infections of the elixir, but excessive use can also
have an adverse effect, that the professionals are well aware. However,
ordinary people only know the advantages of antibiotics, and therefore
suffering from infectious diseases often require doctors to prescribe
antibiotics. So in the end this prescription should not open it, if it should not
open, how should convince the patient to abandon the unreasonable
demands?
One study pointed out that through coordination and communication between patients and doctors, and thus make decisions together, can effectively reduce the extent of antibiotic prescriptions issued. But only for short-term treatment has an impact, whether we can maintain a long time is still unknown.
From Bond University in Queensland, Australia, Professor Peter Coxeter in "Cochrane Database of Systematic Reviews" on-line magazine published a review article in the article, the authors summarize the 10 pairs of patients suffering from respiratory tract infections in the previous survey. These patients had received private care or general academic practice consulting services.
The authors summarize recent decades have done this 10 study, he pointed out that "joint coordination decision" is a relatively new doctor-patient communication.
In the short term, promoting the exchange of personal care doctors and patients to make decisions together can significantly reduce antibiotic prescriptions issued by respiratory infections rate (40%). However, this results in the long term and not very stable.
The researchers believe that the credibility of these results did not reach enables people to change the attitude of resistance to antibiotics.
In the short term, this particular doctor-patient communication can reduce the chance of antibiotic treatment, and will not result in lower patient satisfaction or again consult intentions.
Prior to a review of the article also states: doctor-patient exchange of health professionals and patient guidance is the ability to reduce respiratory tract infection antibiotic prescriptions issued by the chance, the article has the same purpose.
"My view is that no one will exclude this approach (co-decision)," Professor Fan of the University of Fort William Schaffner said, "and the result is indeed very credible."
However, Professor Schaffner also mentioned that part of the study, physicians also need to strengthen the ability to communicate with patients, and these studies indicate that orphans meters have public communication have an effect how long it takes.
Today, doctors are often mentioned in the doctor-patient dialogue vaccine, however, this article needs to remind doctors of the negative effects of antibiotics is explained in detail, which requires a longer period of time, then, also need some conversation skills. Dr. Schaffner conversation cited an example of a pediatrician. "The doctors had tried to persuade patients to reduce the use of antibiotics, but in the end exhausted and had issued a prescription of antibiotics." Risk doctors do not need to conduct a conversation again, but can so that patients can take the initiative to realize that the use of antibiotics
One study pointed out that through coordination and communication between patients and doctors, and thus make decisions together, can effectively reduce the extent of antibiotic prescriptions issued. But only for short-term treatment has an impact, whether we can maintain a long time is still unknown.
From Bond University in Queensland, Australia, Professor Peter Coxeter in "Cochrane Database of Systematic Reviews" on-line magazine published a review article in the article, the authors summarize the 10 pairs of patients suffering from respiratory tract infections in the previous survey. These patients had received private care or general academic practice consulting services.
The authors summarize recent decades have done this 10 study, he pointed out that "joint coordination decision" is a relatively new doctor-patient communication.
In the short term, promoting the exchange of personal care doctors and patients to make decisions together can significantly reduce antibiotic prescriptions issued by respiratory infections rate (40%). However, this results in the long term and not very stable.
The researchers believe that the credibility of these results did not reach enables people to change the attitude of resistance to antibiotics.
In the short term, this particular doctor-patient communication can reduce the chance of antibiotic treatment, and will not result in lower patient satisfaction or again consult intentions.
Prior to a review of the article also states: doctor-patient exchange of health professionals and patient guidance is the ability to reduce respiratory tract infection antibiotic prescriptions issued by the chance, the article has the same purpose.
"My view is that no one will exclude this approach (co-decision)," Professor Fan of the University of Fort William Schaffner said, "and the result is indeed very credible."
However, Professor Schaffner also mentioned that part of the study, physicians also need to strengthen the ability to communicate with patients, and these studies indicate that orphans meters have public communication have an effect how long it takes.
Today, doctors are often mentioned in the doctor-patient dialogue vaccine, however, this article needs to remind doctors of the negative effects of antibiotics is explained in detail, which requires a longer period of time, then, also need some conversation skills. Dr. Schaffner conversation cited an example of a pediatrician. "The doctors had tried to persuade patients to reduce the use of antibiotics, but in the end exhausted and had issued a prescription of antibiotics." Risk doctors do not need to conduct a conversation again, but can so that patients can take the initiative to realize that the use of antibiotics
Anti-fungal immune response mechanism is
Fungi widespread and we live in an environment, our health they also have an important impact. Our
lungs are constantly exposed to the air, and thus come into contact
with a large number of Aspergillus and Fusarium spores, and thus lead to
infection; mucosal system we also often have symbiotic fungi exist,
including the like Candida and mold. Aspergillus and Fusarium infections are the main cause of blindness corneal ulcer disease. Overall,
the annual population suffering from a fungal infection accounted for
25% of the world's population, some serious diseases (candidiasis,
pneumocystosis, cryptococcosis) disease each year with more than 2
million, more than 50% mortality rate. Therefore, the severity of malaria and fungal infections as much as Mycobacterium tuberculosis infection. Depth
understanding of our immune systems, and the characteristics of the
interaction of microorganisms with the outside world can help to take
effective measures to prevent fungal infections. David
M. Underhill professors from Los Angeles Cedars-Sinai Medical Center
and the University of California, Irvine immunization of Eric Pearlman
on "immunity" magazine published a review article, fungal and immune
system interactions in detail Discussion.
With the long-term evolution, the human immune system against infection of the external environment has developed a variety of different immunization strategies. Through the crowd to do the analysis of genetics, combined with their resistance to fungal infection tolerance to find relevant genes. First, phagocytosis in cellular immune defects associated with increased fungal infections. For example: Defect NAPDH protein (a protein capable of generating reactive oxygen component), or a defect mutation neutrophils, can lead to fungal infections. This shows that the role of neutrophils in the anti-fungal infection. Humoral contribution is relatively small, but studies have shown antibodies for anti-fungal infection also has a significant role.
HIV patients often cause some fungal infections, such as oral candidiasis or pneumocystosis. This shows that T cells to anti-fungal infection also has an important role. A recent study found: Mycobacterium tuberculosis infection in susceptible patients in vivo RORC gene mutations, mutations in this gene cause the patient lacks functional RORgamma or RORgamma t, and cause the lymph nodes to induce the missing cells. RORgamma t cells to produce IL-17 is important, so that these patients can not produce IL-17.
A very long time to, lectins (lectin) is considered a key component of fungal infection process. 1060, Miller et al., First found to reduce the expression of mannose binding lectin serum could destroy yeast lysis active ingredient. Since then, a number of studies indicate Dectin1 (a class of C-type lectin receptor) for mucosal candidiasis infection plays an important role. The researchers found that patients with a CARD9 (connected downstream of the C type lectin molecule) defects can cause more serious Candida infections. CARD9 defect can also lead to reduction of Th17 cells and the corresponding cytokine and chemokine production.
Some studies have found that Toll like receptor also plays an important role in fungal infections, including TLR-1, TLR4, TLR6 like.
Inflammatory cytokines IL-1beta release depends on the activation of intracellular inflammation of small bodies as well as IL-1beta precursors cutting. The study found that the mutation NLRP3 (inflammation of the small body) gene can lead to female genital vestibulitis and vulvar candidiasis.
In short, by genetic mutations mass analysis can be found with the active immune signaling molecule has an important impact on the fungal infection.
After that, the author of C-type lectin receptors in the anti-fungal immune responses as well as the main mechanism of antifungal cytokine critical to do a detailed discussion will not go
With the long-term evolution, the human immune system against infection of the external environment has developed a variety of different immunization strategies. Through the crowd to do the analysis of genetics, combined with their resistance to fungal infection tolerance to find relevant genes. First, phagocytosis in cellular immune defects associated with increased fungal infections. For example: Defect NAPDH protein (a protein capable of generating reactive oxygen component), or a defect mutation neutrophils, can lead to fungal infections. This shows that the role of neutrophils in the anti-fungal infection. Humoral contribution is relatively small, but studies have shown antibodies for anti-fungal infection also has a significant role.
HIV patients often cause some fungal infections, such as oral candidiasis or pneumocystosis. This shows that T cells to anti-fungal infection also has an important role. A recent study found: Mycobacterium tuberculosis infection in susceptible patients in vivo RORC gene mutations, mutations in this gene cause the patient lacks functional RORgamma or RORgamma t, and cause the lymph nodes to induce the missing cells. RORgamma t cells to produce IL-17 is important, so that these patients can not produce IL-17.
A very long time to, lectins (lectin) is considered a key component of fungal infection process. 1060, Miller et al., First found to reduce the expression of mannose binding lectin serum could destroy yeast lysis active ingredient. Since then, a number of studies indicate Dectin1 (a class of C-type lectin receptor) for mucosal candidiasis infection plays an important role. The researchers found that patients with a CARD9 (connected downstream of the C type lectin molecule) defects can cause more serious Candida infections. CARD9 defect can also lead to reduction of Th17 cells and the corresponding cytokine and chemokine production.
Some studies have found that Toll like receptor also plays an important role in fungal infections, including TLR-1, TLR4, TLR6 like.
Inflammatory cytokines IL-1beta release depends on the activation of intracellular inflammation of small bodies as well as IL-1beta precursors cutting. The study found that the mutation NLRP3 (inflammation of the small body) gene can lead to female genital vestibulitis and vulvar candidiasis.
In short, by genetic mutations mass analysis can be found with the active immune signaling molecule has an important impact on the fungal infection.
After that, the author of C-type lectin receptors in the anti-fungal immune responses as well as the main mechanism of antifungal cytokine critical to do a detailed discussion will not go
Pfizer & Al build the biggest ever merger nears completion
Bloomberg quoted informed sources said the two conclude a price between $ 370 to 380. But another source said that the document on tax inverted US Treasury
Department on Wednesday released the final merger agreement may hinder
reached.
Al Jianhe Pfizer's enterprise value (EV) in total more than 400 billion US dollars, the purchase price proposed by Pfizer, both total market capitalization of over 340 billion US dollars, the two merged to become one of the largest merger in the history of medicine.
Previously the largest M & A cases in fifteen years ago, America Online (AOL) and Time Warner acquisition, the two companies are market capitalization of about $ 340 billion in total, but then it ended with a huge loss and separation, the case also to become "the biggest failure in the history of" merger.
Pfizer license last month that the company is in talks to buy the real Al built the company after merger will in New York headquarters moved to Ireland. About a year ago, Pfizer abandoned up to $ 118 billion in AstraZeneca (AztraZeneca) acquisition transaction, that transaction tax inversion had its headquarters will be transferred to the UK, but the US Treasury stopped being revoked.
Pfizer, whether it is the acquisition of AstraZeneca or Al build one of the main purpose is through the "tax inversion" to achieve tax avoidance.
Pfizer CEO Ian Read has more than once said that the US onerous tax system allows Pfizer disadvantage is the need to address the most urgent task of Pfizer. If the US government does not change tax policy, tax cuts and the motivation for the company to move to a place of business abroad will not weaken.
Tax inversion is an enterprise registered by changing the way, from high-tax countries to move to low-tax countries, the original should apply a relatively high tax rate becomes applicable tax rate is relatively low, in order to achieve the purpose of tax avoidance. Tax inversion can also be done through the transfer of overseas business after the merger, the "upside acquisitions."
Al built the current market value of $ 117.2 billion, according to Pfizer's proposed purchase price was $ 143 billion, market capitalization of $ 202.8 billion, Pfizer, the two companies are corporate behemoths in the industry. Al built last year which has just been Actavis (Actavis) Pharmaceuticals acquisition price of $ 66 billion, $ 40.5 billion this year again will be its generics business was sold to the Israeli pharmaceutical giant Teva.
Al built to produce botulinum toxin (Botox) and other well-known anti-wrinkle drugs, in the global cosmetics industry, high visibility, over the years has been to more than 10% annual sales growth ahead of the industry, many pharmaceutical companies. Ranked by revenue, Pfizer is the world's largest research-based biopharmaceutical company, it is more than 160 years of history of the old pharmaceutical companies.
This year is the pharmaceutical industry mergers and acquisitions "bumper." For example, US pharmaceutical companies Abbvie (AbbVie) to US $ 21 billion acquisition of anticancer drug manufacturers Pharmacyclis, and Pfizer Inc. (Pfizer) to $ 17 billion acquisition of US medicines and medical equipment manufacturers liters Switzerland (Hospira).
Al Jianhe Pfizer's enterprise value (EV) in total more than 400 billion US dollars, the purchase price proposed by Pfizer, both total market capitalization of over 340 billion US dollars, the two merged to become one of the largest merger in the history of medicine.
Previously the largest M & A cases in fifteen years ago, America Online (AOL) and Time Warner acquisition, the two companies are market capitalization of about $ 340 billion in total, but then it ended with a huge loss and separation, the case also to become "the biggest failure in the history of" merger.
Pfizer license last month that the company is in talks to buy the real Al built the company after merger will in New York headquarters moved to Ireland. About a year ago, Pfizer abandoned up to $ 118 billion in AstraZeneca (AztraZeneca) acquisition transaction, that transaction tax inversion had its headquarters will be transferred to the UK, but the US Treasury stopped being revoked.
Pfizer, whether it is the acquisition of AstraZeneca or Al build one of the main purpose is through the "tax inversion" to achieve tax avoidance.
Pfizer CEO Ian Read has more than once said that the US onerous tax system allows Pfizer disadvantage is the need to address the most urgent task of Pfizer. If the US government does not change tax policy, tax cuts and the motivation for the company to move to a place of business abroad will not weaken.
Tax inversion is an enterprise registered by changing the way, from high-tax countries to move to low-tax countries, the original should apply a relatively high tax rate becomes applicable tax rate is relatively low, in order to achieve the purpose of tax avoidance. Tax inversion can also be done through the transfer of overseas business after the merger, the "upside acquisitions."
Al built the current market value of $ 117.2 billion, according to Pfizer's proposed purchase price was $ 143 billion, market capitalization of $ 202.8 billion, Pfizer, the two companies are corporate behemoths in the industry. Al built last year which has just been Actavis (Actavis) Pharmaceuticals acquisition price of $ 66 billion, $ 40.5 billion this year again will be its generics business was sold to the Israeli pharmaceutical giant Teva.
Al built to produce botulinum toxin (Botox) and other well-known anti-wrinkle drugs, in the global cosmetics industry, high visibility, over the years has been to more than 10% annual sales growth ahead of the industry, many pharmaceutical companies. Ranked by revenue, Pfizer is the world's largest research-based biopharmaceutical company, it is more than 160 years of history of the old pharmaceutical companies.
This year is the pharmaceutical industry mergers and acquisitions "bumper." For example, US pharmaceutical companies Abbvie (AbbVie) to US $ 21 billion acquisition of anticancer drug manufacturers Pharmacyclis, and Pfizer Inc. (Pfizer) to $ 17 billion acquisition of US medicines and medical equipment manufacturers liters Switzerland (Hospira).
2015年11月17日星期二
Merck whole eight weeks of oral triple therapy regimen HCV success rate> 90%
2015
Annual Meeting of the American Association for Study of Liver Diseases
(AASLD 2015) was held in San Francisco on 13-17 of this month. Recently,
Merck (Merck & Co) in conference to announce the company's two
kinds of experimental research of the whole oral, triple Hepatitis C
therapy (grazoprevir / MK-36822 / elbasvir, grazoprevir / MK-3682 /
MK-84084) of 2 randomized, open-label phase II study (C-CREST 1, C-CREST 2) of Part A data. Wherein,
C-CREST 1 study in naïve, non-cirrhotic hepatitis C genotype 1 and
genotype 2 (HCV GT-1, GT-2) in patients with conduct, C-CREST 2 study in
naïve, non-cirrhotic genotype 3 hepatitis C (HCV GT-3) conducted in patients. Institute recruited 240 patients completed the 8-week treatment and follow-up of 12 weeks after the end of treatment, the primary endpoint is virologic response 12 weeks (SVR12, virological cure). 2
kinds of hepatitis Full oral triple therapy, grazoprevir (MK-5172) is
an HCV NS3 / 4A protease inhibitor, MK-3682 is an oral prodrug HCV NS5B
nucleoside analog protease inhibitors, elbasvir (MK- 8742) and MK-8408 were HCV NS5A replication complex inhibitor.
Data show that the whole oral triple therapy (grazoprevir / MK-3682 / MK-84084) for 8 weeks treatment programs across the hepatitis C genotype 1, 2 groups of viral cure rates (SVR12) exceeds 90%, the study strong efficacy data observed to support the further continue to explore this novel all-oral HCV triple therapy efficacy and safety in the hepatitis C population. Currently, Merck has launched the Part B study grazoprevir / MK-3682 / MK-84084 triple therapy CREST II clinical development project, will investigate the efficacy and safety of the triple therapy treatment cycle in a variety of different patient populations, including early Hepatitis C treatment (with or without), HIV / HCV co-infection, (pegylated interferon / ribavirin) after hepatitis C treatment.
Data show that the whole oral triple therapy (grazoprevir / MK-3682 / MK-84084) for 8 weeks treatment programs across the hepatitis C genotype 1, 2 groups of viral cure rates (SVR12) exceeds 90%, the study strong efficacy data observed to support the further continue to explore this novel all-oral HCV triple therapy efficacy and safety in the hepatitis C population. Currently, Merck has launched the Part B study grazoprevir / MK-3682 / MK-84084 triple therapy CREST II clinical development project, will investigate the efficacy and safety of the triple therapy treatment cycle in a variety of different patient populations, including early Hepatitis C treatment (with or without), HIV / HCV co-infection, (pegylated interferon / ribavirin) after hepatitis C treatment.
订阅：
博文 (Atom)